Clinical Trials Logo

Clinical Trial Summary

The goal of this observational study is to assess the risk of viral infections in patients receiving hematopoietic stem cell transplantation (HSCT) from a haploidentical donor compared to those who receive HSCT from a HLA-matched donor. The main question it aims to answer is: to describe which viruses are replicating in the blood of the above two patient groups on the day of transplantation and at 1, 3 and 6 months after transplantation. Blood samples taken as part of routine care on the day of transplantation and at 1, 3 and 6 months post-transplantation visits are analyzed and the types and amount of viruses detected in the two groups of patients are described.


Clinical Trial Description

Geneva University Hospitals are one of the three centers performing allogeneic HSCT in Switzerland. Since several years the Division of infectious diseases runs a collaborative research program with the Division of Hematology. In 2015 the two divisions jointly created a prospective cohort of allo-HSCT patients called: "Infectious diseases in hematopoietic stem cell transplant patients cohort" enrolling potentially all adult patients engrafted in our center since 2015 (CCER protocol 15-120 and relative amendments). The cohort compiles clinical data on hematological and infectious complications occurring up to one year after transplantation and biological specimen collected systematically until up to 2 years after transplantation, which are stored in a joint biobank. ;


Study Design


Related Conditions & MeSH terms

  • Haploidentical Hematopoietic Stem Cell Transplantation

NCT number NCT05622032
Study type Observational
Source University Hospital, Geneva
Contact
Status Active, not recruiting
Phase
Start date September 20, 2022
Completion date October 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06041893 - Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Recruiting NCT02014506 - Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents Phase 1/Phase 2
Recruiting NCT05166967 - Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation Phase 4
Active, not recruiting NCT04778618 - Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT03236220 - Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation Phase 2
Recruiting NCT06381817 - Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients Phase 3